Tr1X
Engineering cures for patients with autoimmune & inflammatory diseases.
San Diego, United States
46 employees
Total: $125.00M
Biotechnology, Health Care +1
General Information
San Diego, United States
BounceWatch is an independent company data service, not affiliated with Tr1X. To contact Tr1X, visit tr1x.bio.
Is this your company?
Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.
Get Verified
How does Tr1X compare?
A PDF of Tr1X and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.
This takes a few seconds: we look beyond our own index too.
Meeting Tr1X soon?
A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample
Discover More
United States Market
Biotechnology
About Tr1X
Business keywords: cellular immunotherapies, autoimmune diseases, inflammatory diseases, immune system, cell therapy, proprietary platform, immune modulation, homeostasis, tolerance, La Jolla, California
Funding Rounds & Investors (3)
View All| Funding Stage | Amount | Investors | Lead Investors | Date |
|---|---|---|---|---|
| Early VC | $50.00M | - |
|
01 Oct 2025 |
| Series A | $75.00M | 3 |
|
01 Jan 2024 |
| Spinout | Undisclosed | 1 |
Stanford University
|
01 Jan 2018 |
Tr1X Alternatives & Competitors
View All Alternatives
Rebalancing Immune Function for Chronic Inflammatory and Autoimmune Diseases
Leading the Next Frontier of Cell Therapy
We develop first-in-class CD31 checkpoint agonists for the treatment of auto-immune diseases
FAQ About Tr1X
Source: BounceWatch company record for Tr1X, https://bouncewatch.com/company/tr1x, updated 9 June 2026. When citing, please name BounceWatch and link this page.
